Guardant Health (GH): director Tariq Musa sells $5591 in stock

Director Tariq Musa of Guardant Health , Inc. (NASDAQ:GH), a $5.7 billion healthcare company that has seen its stock surge over 51% in the past year, sold 116 shares of common stock on July 17, 2025, according to a Form 4 filing with the Securities and Exchange Commission. InvestingPro analysis suggests the stock is currently trading slightly above its Fair Value. The shares were sold at a price of $48.2, with the total transaction amounting to $5591. Following the transaction, Musa directly owns 7324 shares of Guardant Health. The company maintains strong liquidity with a current ratio of 4.11, and according to InvestingPro, which offers comprehensive analysis through its Pro Research Report, the stock has demonstrated robust momentum with a 29% gain over the past six months.

In other recent news, Guardant Health has received significant attention following the announcement that its Shield multi-cancer detection test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). This designation aims to expedite the development and review of medical devices that could improve the diagnosis of life-threatening diseases. Guardant Health’s Shield test, which screens for multiple cancer types, was also selected by the National Cancer Institute for the Vanguard Study due to its robust performance in cancer prediction. Meanwhile, Mizuho (NYSE:MFG) has raised its price target for Guardant Health to $65.00, citing an optimistic outlook for the Shield test following its FDA designation. Evercore ISI maintains a $60.00 price target, projecting over 20% top-line growth through 2027 and highlighting potential profitability by fiscal year 2028. UBS analysts have reiterated their Buy rating with a $70.00 price target, emphasizing Guardant Health’s leadership in tumor profiling and the promising inclusion of its Shield test in national cancer screening guidelines. Leerink Partners also maintains an Outperform rating, noting Guardant Health’s strong position in the diagnostics market and potential for growth. These developments underscore Guardant Health’s strategic advancements and potential in the healthcare sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.